The limited role of serum galactomannan assay in screening for invasive pulmonary aspergillosis in allogeneic stem cell transplantation recipients on micafungin prophylaxis: a retrospective study

다국어 초록 (Multilingual Abstract)

Background: We evaluated the outcomes of serum galactomannan (GM) assay for the screening of invasive pulmonary aspergillosis (IPA) in allogeneic hematopoietic stem cell trans-plantation (alloHSCT) recipients while on primary antifungal prophylaxis (PAP).
Methods: This study included patients with hematologic disorders who underwent alloHSCT from January 2013 to November 2015. Patients received routine PAP with fluconazole before 2014 and micafungin after 2014; serum GM tests were performed and retrospectively analyzed. The sensitivity, specificity, positive predictive value (PPV), and negative pre-dictive value (NPV) of serum GM tests for detection of probable/proven IPA were evaluated. The serial change of serum GM levels was illustrated on a time series plot.
Results: A total of 136 alloHSCT recipients at Seoul National University Hospital were included in the study. Fluconazole was administered in 72 patients for PAP, while micafungin was administered in the remaining 64 patients. The overall sensitivity, specificity, and NPV of serum GM assays were 95.8% (95% confidence interval [CI] 78.9‒99.9%), 93.8% (95% CI 91.7‒95.5%), and 99.8% (95% CI 99.1‒100.0%), respectively. However, the PPV of GM tests was relatively low at 35.4% (95% CI 23.9‒48.2%). The serial change in serum GM levels differed according to the antifungal agents used. With effective PAP using mica-fungin, serial serum GM levels showed zero order kinetics during the neutropenic period.
Conclusion: Although the serum GM assay is a sensitive and specific test for detecting IPA in alloHSCT recipients, its role for routine surveillance in an era of effective PAP with micafungin is limited.

참고문헌 (Reference)

1 Borlenghi E, "Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates" 86 : 205-210, 2007

2 Hiramatsu Y, "Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation" 88 : 588-595, 2008

3 Reid MC, "Use of methodological standards in diagnostic test research. Getting better but still not good" 274 : 645-651, 1995

4 Ambasta A, "The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients" 53 : 531-557, 2015

5 Maertens J, "Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients : a prospective validation" 97 : 1604-1610, 2001

6 De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group(EORTC/MSG)Consensus Group" 46 : 1813-1821, 2008

7 Cornely OA, "Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia" 356 : 348-359, 2007

8 Ullmann AJ, "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease" 356 : 335-347, 2007

9 Schisterman EF, "Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples" 16 : 73-81, 2005

10 Aubry A, "Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders" 44 : 389-394, 2006

11 van Burik JA, "Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation" 39 : 1407-1416, 2004

12 Boutboul F, "Invasive aspergillosis in allogeneic stem cell transplant recipients : increasing antigenemia is associated with progressive disease" 34 : 939-943, 2002

13 Upton A, "Invasive aspergillosis following hematopoietic cell transplantation : outcomes and prognostic factors associated with mortality" 44 : 531-540, 2007

14 Racil Z, "Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum" 45 : 3141-3142, 2007

15 Surmont I, "Gluconate-containing intravenous solutions : another cause of false-positive galactomannan assay reactivity" 45 : 1373-, 2007

16 Donnelly JP, "Galactomannan detection and diagnosis of invasive aspergillosis" 50 : 1070-1071, 2010

17 Asano-Mori Y, "False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation" 61 : 411-416, 2008

18 Sulahian A, "False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam" 349 : 2366-2367, 2003

19 Marchetti O, "ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients" 47 : 846-854, 2012

20 Cuenca-Estrella M, "Detection and investigation of invasive mould disease" 66 (66): i15-i24, 2011

21 Cordonnier C, "Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis" 15 : 81-86, 2009

22 Subirà M, "Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis" 82 : 80-82, 2003

23 Latgé JP, "Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus" 62 : 5424-5433, 1994

24 Mennink-Kersten MA, "Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection" 363 : 325-327, 2004

25 Marr KA, "Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay" 40 : 1762-1769, 2005

26 Hirata Y, "Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies" 51 : 853-859, 2010

27 Robenshtok E, "Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation : systematic review and meta-analysis" 25 : 5471-5489, 2007

28 Hashino S, "Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation" 87 : 91-97, 2008

29 Sirohi B, "A study to determine the safety profile and maximum tolerated dose of micafungin(FK463)in patients undergoing haematopoietic stem cell transplantation" 38 : 47-51, 2006